Form 4: Beauty Health Director Granted 57,692 RSUs

Philippe Schaison, a director at The Beauty Health Company, was granted 57,692 restricted stock units vesting based on continued service.

Summary

• Philippe Schaison, a director of The Beauty Health Company (SKIN), was granted 57,692 restricted stock units (RSUs) on November 13, 2025.
• Each RSU represents a contingent right to receive one share of Class A Common Stock of The Beauty Health Company.
• The RSUs are subject to time-vesting conditions.
• Vesting will occur on the earlier of the one-year anniversary of the grant date or the date of the Company's 2026 Annual Meeting of Stockholders.
• Vesting is contingent upon Mr. Schaison's continued service as a member of the Company's board of directors through the vesting date.

Sentiment

Score: 7

Explanation: The grant of RSUs to a director is a positive event as it aligns management's interests with shareholders. It's a standard compensation practice and doesn't indicate any negative operational or financial issues.

Positives

• The grant of restricted stock units to a director aligns their long-term interests with those of the shareholders.
• Equity compensation is a standard practice for attracting and retaining qualified board members.

Negatives

• The RSUs do not provide immediate liquidity to the director as they are subject to vesting conditions.
• The value of the compensation is tied to the future performance of the company's stock price.

Risks

• The RSUs are subject to time-vesting conditions, meaning the director must continue service until the vesting date to receive the shares.
• The ultimate value of the RSUs is dependent on the market price of The Beauty Health Company's Class A Common Stock at the time of vesting.

Future Outlook

The grant of restricted stock units indicates an expectation of continued service from Director Philippe Schaison through at least the one-year anniversary of the grant or the 2026 Annual Meeting of Stockholders, aligning his future incentives with the company's performance.

Industry Context

The grant of restricted stock units to a non-employee director is a common form of equity compensation in publicly traded companies across various industries, including the beauty and health sector. It serves to align the interests of the board with long-term shareholder value.

Comparison to Industry Standards

• Equity grants, such as RSUs, are a standard component of director compensation packages in public companies, comparable to practices at peers in the consumer health and beauty industry.
• The vesting schedule, tied to continued service, is typical for such grants, ensuring directors remain engaged and committed to the company's strategic objectives.

Corporate Governance

Related Party Transactions

• The grant of 57,692 restricted stock units to Philippe Schaison, a director of The Beauty Health Company, constitutes a related party transaction as it involves compensation to a member of the board of directors. This is a standard form of director compensation.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially leading to decisions that enhance long-term shareholder value.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The RSUs will vest on the earlier of the one-year anniversary of the grant date or the date of the 2026 Annual Meeting of Stockholders, contingent on continued service.

Key Dates

Keywords

Beauty Health Co, SKIN, Form 4, Restricted Stock Units, RSUs, Director Compensation, Equity Grant, Philippe Schaison, Insider Transaction